ARQT icon

Arcutis Biotherapeutics
ARQT

Overview Fund Trends Analyst Outlook Journalist POV
Buy
Hold
Sell

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
Avg. target
$20
4% downside
High target

2 analyst ratings

positive
1  neutral
50%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
Needham
Needham
Serge Belanger
71% 1-yr ARQT win rate
7 Aug ‘25 2 months ago
Goldman Sachs
Goldman Sachs
Richard Law
25 Jul ‘25 2 months ago